

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Grainger et al. Customer No. : 21003  
Serial No. : 09/754,775 Group Art Unit : 1617  
Filed : 01/04/2001  
Examiner : Kim, Jennifer M.  
For : PREVENTION AND TREATMENT OF CARDIOVASCULAR  
PATHOLOGIES WITH TAMOXIFEN ANALOGUES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

I hereby certify that this paper is being deposited with the United States  
Postal Service as First-Class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,  
on:

August 4, 2006

Date of Deposit

Van Nguyen

Attorney Name

56,571

PTO Reg. No.

August 4, 2006

Date of Signature

  
Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicant brings to the attention of  
the Examiner the document listed on the attached Form PTO-1449 and respectfully requests  
that the listed document be considered by the Examiner and made of record in the above-  
captioned application.

1. Sato, Yasufumi. "TGF- $\beta$  and Vascular Lesions: Neoangiogenesis and  
Atherosclerosis", Experimental Medicine [Jikken igaku], Chapter 2: TGF-  $\beta$   
Pathophysiology, Vol. 10, No. 15, 1992, pp. 94-98 (1908-1912).

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and the applicant determines that the cited document does not constitute "prior art" under United States law, the applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of the document.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claim of the present application.

This Information Disclosure Statement is being filed after the mailing date of a first office action. Therefore, applicants have authorized the Commissioner to charge the fee of \$180.00 to our deposit account. If any additional fee is due, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:

  
Van Nguyen  
Patent Office Reg. No. 56,571

30 Rockefeller Plaza, 44th Floor  
New York, NY 10012-4498  
Attorneys for Applicants  
212-408-2500

Enclosures

<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. 074973.0117	Serial No. 09/754,775
	Applicant Grainger et al.	
	Filing Date January 4, 2001	Group 1617
	Examiner Kim, Jennifer M.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1.	Sato, Yasufumi. "TGF- $\beta$ and Vascular Lesions: Neoangiogenesis and Atherosclerosis", Experimental Medicine [Jikken igaku], Chapter 2: TGF- $\beta$ Pathophysiology, Vol. 10, No. 15, 1992, pp. 94-98 (1908-1912).

NY02:556492.1

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.